The DOI matches its Crossref record; 58 of the 60 references it cites were found in a registry or an index.
Influence of fluoxetine on the ability of bupropion to modulate extracellular dopamine and norepinephrine concentrations in three mesocorticolimbic areas of rats
Abstract
The finding that serotonin (5-HT) can modulate dopamine (DA) and norepinephrine (NE) release in the brain has led us to hypothesize that fluoxetine, a selective 5-HT reuptake inhibitor, may influence the ability of bupropion, a preferential DA and NE dual reuptake inhibitor, to modulate extracellular DA and NE concentrations in some brain areas. The present study was designed to evaluate this hypothesis by assessing the effects of fluoxetine on bupropion-induced changes in extracellular monoamine concentrations by means of in vivo microdialysis. Three mesocorticolimbic areas including hypothalamus (Ht), prefrontal cortex (Pfc) and nucleus accumbens (Acb) were selected based on their relevance to depression and antidepressant actions. In the Ht of untreated rats, bupropion dose-dependently (s.c.) increased extracellular DA and NE concentrations either in single injection study or in sequential injection study. Thus, 10 mg/kg of bupropion had no effect on the DA and NE concentrations, while 30 mg/kg of bupropion induced transient but significant increases (about 240% of the baselines), and 100 mg/kg of bupropion induced marked and persistent increases (over 600% of the baselines) in the DA and NE concentrations. In the rats pre-treated with fluoxetine (10 mg/kg, s.c., 90 min interval), the threshold dose of bupropion (10 mg/kg) significantly increased the DA and NE concentrations to more than 350% of the baselines, and 30 mg/kg of bupropion markedly increased the DA and NE concentrations to more than 570% of the baselines in the Ht. The fluoxetine pre-treatment also potentiated the DA increases induced by 10 mg/kg of bupropion in the Pfc (260% for bupropion alone vs 357% for the combination) and in the Acb (224% vs 645%). The bupropion-induced NE increases were potentiated by fluoxetine mainly in the Ht. Bupropion did not significantly affect the extracellular 5-HT concentrations in all the 3 brain areas tested. In summary, the present study demonstrated that bupropion can increase extracellular DA and NE concentrations in several mesocorticolimbic areas, which may have an impact on bupropion's antidepressant actions. Furthermore, fluoxetine can potentiate the bupropion-induced DA and NE increases, which may produce more effective and rapid antidepressant actions.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Microdialysis studies indicate that bupropion treatment increases extracellular concentrations of DA and norepinephrine (NE) in the hypothalamus, PFC, and NAcc [216].”
From Mechanistic insights into nicotine withdrawal (2011) · cites this paper as [216]
Citations
Cites
The rat brain in stereotaxic coordinates
Palkovits, M. (1983) · Neuropeptides · doi:10.1016/0143-4179(83)90049-5 · Cited by 28,959
The Rat Brain in Stereotaxic Coordinates
Paxinos, G., & Watson, C. (1983) · Elsevier eBooks · doi:10.1016/c2009-0-63235-9 · Cited by 28,585
Bupropion: a review of its mechanism of antidepressant activity.
Ascher, J. A., Cole, J. O., Colin, J. N., Feighner, J. P., Ferris, R. M., Fibiger, H. C., Golden, R. N., Martin, P., Potter, W. Z., & Richelson, E. (1995) · PubMed · Cited by 680
Wong, D. T., Horng, J. S., Bymaster, F. P., Hauser, K. L., & Molloy, B. B. (1974) · Life Sciences · doi:10.1016/0024-3205(74)90345-2 · Cited by 480
Crewe, H. K., Lennard, M., Tucker, G., Woods, F. R., & Haddock, R. E. (1992) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1992.tb04134.x · Cited by 468
Hervé, D., Pickel, V. M., JOH, T. H., & Beaudet, A. (1987) · Brain Research · doi:10.1016/0006-8993(87)91588-5 · Cited by 372
Morphological and Functional Aspects of Central Monoamine Neurons
Fuxé, K., Hökfelt, T. G. M., & Ungerstedt, U. (1970) · International review of neurobiology · doi:10.1016/s0074-7742(08)60167-1 · Cited by 352
Tanda, G., Carboni, E., Frau, R., & Chiara, G. D. (1994) · Psychopharmacology · doi:10.1007/bf02244785 · Cited by 320
Millan, M. J., Dekeyne, A., & Gobert, A. (1998) · Neuropharmacology · doi:10.1016/s0028-3908(98)00078-1 · Cited by 290
Dopamine and depression: A review of recent evidence. I. Empirical studies
Willner, P. (1983) · Brain Research Reviews · doi:10.1016/0165-0173(83)90005-x · Cited by 273
Research works printed but not linked: 5
- Dubini, 1997, NE-selective versus 5-HT-selective antidepressant therapy: differential effects on social functioning, Journal of Psychopharmacology, 11, S17
- Ferris, 1993, Mechanism of antidepressant activity of bupropion, Journal of Clinical Psychiatry Monographs, 11, 2
- Fuller, 1992, Clinical applications of 5-HT uptake inhibitors, vol. 85, 255
- Gessa, 1994, Dopaminergic system in antidepressant action, Neuropsychopharmacology, 10, 47S
- Mayle, 1991, Elevation of catecholaminergic metabolite levels in the rat hypothalamus by an agonist of serotonin IC/2 receptors, MK212 (6-chloro-2(1-piperazinyl)pyrazine), Society for Neuroscience, 17, 407
Cited by
Sorted by citations
The dual pathway model of AD/HD: an elaboration of neuro-developmental characteristics
Sonuga-Barke, E. J. S. (2003) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2003.08.005 · Cited by 816
Stahl, S. M., Pradko, J., Haight, B. R., Modell, J. G., Rockett, C. B., & Learned-Coughlin, S. (2004) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.v06n0403 · Cited by 495
The Role of Nicotine in Smoking: A Dual-Reinforcement Model
Caggiula, A. R., Donny, E. C., Palmatier, M. I., Liu, X., Chaudhri, N., & Sved, A. F. (2008) · Nebraska Symposium on Motivation · doi:10.1007/978-0-387-78748-0_6 · Cited by 226
Mazloum‐Ardakani, M., Beitollahi, H., Amini, M. K., Mirkhalaf, F., & Abdollahi‐Alibeik, M. (2010) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2010.09.011 · Cited by 224
Cryan, J. F., Bruijnzeel, A. W., Skjei, K. L., & Markou, A. (2003) · Psychopharmacology · doi:10.1007/s00213-003-1445-7 · Cited by 223
Metadata
- Authors
- Li, S. X.-M., Perry, K. W., & Wong, D. T.
- Affiliations
- Eli Lilly (United States) (US)
- Corresponding author
- Perry, Kenneth W
- ORCID
- Wong, David T
- Venue
- Neuropharmacology
- Publisher
- Elsevier BV
- Published
- 2002-02
- Volume
- 42
- Issue
- 2
- Pages
- 181-190
- ISSN
- 0028-3908 (ISSN-L)
- OpenAlex
- W1971669832
- Cited by
- 156
- References
- 60
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 1 · 2021: 2 · 2020: 5 · 2019: 3 · 2018: 3 · 2017: 5 · 2016: 4 · 2015: 4 · 2014: 4 · 2013: 14 · 2012: 11
- FWCI
- 3.95
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Neuropharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- fluoxetine, bupropion, extracellular dopamine, serotonin, mesocorticolimbic system, hypothalamus, prefrontal cortex, nucleus accumbens, monoamine release, antidepressant mechanism, selective serotonin reuptake inhibitors, depression, drug interactions, microdialysis, rats
- MeSH terms
- Animals, Cerebral Cortex, Chromatography, High Pressure Liquid, Dopamine, Extracellular Space, Fluoxetine, Hematocrit, Limbic System, Male, Norepinephrine, Bupropion, Rats, Sprague-Dawley, Selective Serotonin Reuptake Inhibitors, Microdialysis, Dopamine Uptake Inhibitors, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
